Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
verywellhealth3d
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
Yahoo Finance4d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week ... today announced that data from the Phase 3 trial (EMBER-3) for ...
Outsourcing-pharma4d
Tirzepatide prevents type 2 diabetes in 99% of prediabetic patients for 3 years
Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...
The Pharma Letter4d
Momentum flagging, a Phase III data win spurs tirzepatide
Results from the Phase III SURMOUNT-1 trial show strong benefit in using the dual GLP-1/GIP agonist to lessen diabetes risk ...
FiercePharma4d
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
labiotech5d
Sleep apnea: biotechs snore points in the therapeutic space
Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...